HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about another FDA reversal, pharma’s M&A spree and much more
The FDA will reconsider approving a gene therapy for a rare childhood brain disorder it previously rejected, following recent leadership changes. The U.S. also launched a trade investigation into Germany's plan to reduce pharmaceutical spending, which faced industry opposition and was revised.
Mentioned
Related Signal
Adjacent reporting
- STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection
- STAT+: FDA to reconsider treatment for rare cancer after surprise rejection
- STAT+: FDA to reconsider treatment for rare cancer after its surprise rejection
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
- STAT+: Pharmalittle: We’re reading about U.S. biotech’s China problem, a Regeneron flop, and much more
- STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more